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Abstract
The paradigm for pathogenic autoimmunity is the generation of
high-titre, affinity-matured autoantibodies to a restricted family of
autoantigens, in the appropriate genetic context. Genetic determi-
nants of autoimmunity are largely found within the major histo-
compatibility complex (MHC) and the ‘genotype to serotype to
phenotype’ concept is supported in a number of autoimmune
diseases, where both genotype and serotype are well established.
The serotype is autoantigen-driven, with evidence of epitope
spreading as the disease evolves from asymptomatic to patho-
genic autoimmunity. In rheumatoid arthritis and multiple sclerosis,
where the autoantigens are poorly characterised, the use of an
array in animal models may produce a hint of what happens in
human disease. A more complete picture will be obtained from
animals transgenic for human MHC, immunised with known human
autoantigens.
Epitope spreading in animal models of
rheumatoid arthritis and multiple sclerosis
In a recent issue, Kidd and colleagues [1] have attempted an
analysis of epitope spreading in murine collagen-induced
arthritis and experimental autoimmune encephalomyelitis as
models of rheumatoid arthritis (RA) and multiple sclerosis
(MS). This is a courageous undertaking, because the major
histocompatibility complex (MHC) differs between mouse and
man and, therefore, any MHC-dependent autoimmune
response may also differ. In the human form of both diseases,
the autoantigens remain poorly characterised. In RA,
citrullinated antigens are likely to be the major targets of the
autoimmune response. This conclusion is supported by the
high specificity of antibodies to cyclic citrullinated peptides
(CCPs) both in diagnosing and predicting disease. The
specific target antigens include citrullinated fibrinogen,
citrullinated vimentin, citrullinated collagen type II (reviewed in
[2]) and, more recently, citrullinated α-enolase [3]. In α-
enolase, there is evidence of an independent immune
response to multiple citrullinated epitopes within the molecule
[3]. In MS, a number of candidate autoantigens are asso-
ciated with myelin, though the predictive and diagnostic value
of their associated autoantibodies is disappointing [4]. In
both murine models, the primary autoantigen is the protein
used to induce the disease. However, in RA, it is clear that
native collagen is not ‘the’ autoantigen and the intense
antibody response to proteolipid protein, seen in experimental
autoimmune encephalomyelitis, is not present in MS.
Kidd and colleagues attempt a non-prejudicial approach to
dealing with the range of autoantigens that might be
pathogenic in RA and MS by array technology. They used
253 antigens for their synovial array and 406 for their myelin
array. This, of course, is a tiny fraction of the proteome and
their choice had to be restricted to some of the antigens
described as candidates in the previous literature. In spite of
these limitations, they showed that antibodies to other candi-
date antigens, including citrullinated peptides, developed
during the course of both diseases. They interpreted this as
being due to intermolecular epitope spreading arising from
the expression of citrullinated proteins as neoantigens in
inflamed tissue. Some support for this hypothesis was
provided by anti-citrulline immunoblotting, which demon-
strated an increase of citrullinated proteins in both inflamed
synovium and brain tissue. Other interpretations, however,
include the possibility that antibodies to citrullinated proteins
arise as a result of polyclonal activation as part of the ‘natural
antibody’ response to adjuvant. Kidd and colleagues did not
use an adjuvant-only immunised group of mice as controls,
nor did they distinguish IgM from IgG antibodies. A further
control not examined was the testing of the CII immunised
mice on the myelin array or vice versa. A controversial finding
in this study was the demonstration of citrulline specificity for
the antibodies to citrullinated peptides. This has also been
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reported in one previous study of collagen-induced arthritis
[5], though other studies have found equal binding to both
citrullinated and arginine-containing control peptides [6]. In
RA, the anti-CCP response reflects the genotype-serotype-
phenotype model, with antibodies to citrullinated proteins
being closely correlated with the presence of the MHC
shared epitope [7] and it has been argued that the shared
epitope is required to present citrulline containing peptides to
responder T cells [8]. Therefore, the most convincing murine
model of RA is that of the recently reported DR4-IE
transgenic mouse immunised with citrullinated fibrinogen [9].
The impressive, though often uncontrolled, array of data that
arises from this sort of work is often regarded as hypothesis-
generating rather than hypothesis-testing. The study from Kidd
and colleagues [1] falls in the former group, in that it provides
more questions than answers. In the case of RA, some of the
answers are already partially addressed by the recent reports
of new disease-specific autoantibodies. In MS, the B cell
autoantigens remain poorly characterised. Nevertheless, the
authors have presented an exciting new model to provide
some of the answers in the future. Now that we know more
about the citrullinated antigens associated with the anti-CCP
response and the requirement for specific MHC alleles, the
use of transgenic animals could go a long way to analyse the
autoimmune response in RA. In MS, where the autoimmune
response appears to be less MHC-restricted, better definition
of the human autoantigens is required for further progress.
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